Exponent, Inc. (EXPO)
| Market Cap | 3.03B -24.6% |
| Revenue (ttm) | 551.14M +6.3% |
| Net Income | 108.93M +3.2% |
| EPS | 2.14 +4.8% |
| Shares Out | 49.25M |
| PE Ratio | 28.72 |
| Forward PE | 25.31 |
| Dividend | $1.24 (2.02%) |
| Ex-Dividend Date | Jun 5, 2026 |
| Volume | 394,145 |
| Open | 63.17 |
| Previous Close | 63.44 |
| Day's Range | 60.73 - 63.34 |
| 52-Week Range | 60.73 - 81.95 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 85.00 (+38.39%) |
| Earnings Date | Apr 30, 2026 |
About EXPO
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and ... [Read more]
Financial Performance
In fiscal year 2025, Exponent's revenue was $536.76 million, an increase of 3.52% compared to the previous year's $518.49 million. Earnings were $106.01 million, a decrease of -2.75%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for EXPO stock is "Buy." The 12-month stock price target is $85.0, which is an increase of 38.39% from the latest price.
News
Exponent price target lowered to $75 from $85 at UBS
UBS analyst Joshua Chan lowered the firm’s price target on Exponent (EXPO) to $75 from $85 and keeps a Neutral rating on the shares. The company posted a “solid” quarter
Exponent increases share repurchase authorization by $50M
Exponent’s (EXPO) board of directors increased the company’s authority to repurchase shares of its common stock by $50M. This is in addition to the $17.7M available for repurchase as of
Exponent sees FY26 revenues before reimbursements to grow in high-single digits
Sees FY26 EBITDA to be 27.6%-28.1% of revenues before reimbursements.
Exponent Earnings Call Transcript: Q1 2026
Q1 2026 saw double-digit revenue and earnings growth, driven by strong demand in AI, energy, and regulatory sectors. Leadership transitions and expanded share repurchases signal confidence in long-term growth. Guidance calls for continued high single-digit revenue growth and robust margins.
Exponent reports Q1 EPS 59c, consensus 61c
Reports Q1 revenue $166.3M, consensus $153.02M.
Exponent sees Q2 revenues before reimbursements growing in high-single digits
Sees Q2 EBITDA to be 27.0%-27.8% of revenues before reimbursements.
Exponent Reports First Quarter 2026 Financial Results
MENLO PARK, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the first quarter of fiscal year 2026 ended April 3, 2026.
Exponent Declares Regular Quarterly Dividend for Q2 2026 and Increases Stock Repurchase Authorization by $50 Million
MENLO PARK, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.31 per share of common sto...
Exponent to Announce First Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on April 30, 2026
MENLO PARK, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report First Quarter of fiscal year 2026 financial results for the period ended April...
Exponent names Eric Anderson CFO, chairman Paul Johnston to retire
Exponent (EXPO) announced its appointment of Eric Anderson to CFO, effective May 1 and reporting to Catherine Corrigan, CEO and the appointment of Karen Richardson as chairman of the board
Exponent Elevates John Pye to President and Eric Anderson to CFO Reporting to Catherine Corrigan, CEO; Rich Schlenker to Remain as Executive VP and to Stand for Election to Board of Directors
MENLO PARK, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq:EXPO), a leading engineering and scientific consulting firm, today announced its appointment of John Pye to President and ...
Exponent price target lowered to $95 from $100 at JPMorgan
JPMorgan lowered the firm’s price target on Exponent (EXPO) to $95 from $100 and keeps an Overweight rating on the shares. The firm updated models in the North American small-cap
Exponent price target raised to $85 from $81 at UBS
UBS analyst Joshua Chan raised the firm’s price target on Exponent (EXPO) to $85 from $81 and keeps a Neutral rating on the shares. The Q4 results and 2026 guidance
Exponent Earnings Call Transcript: Q4 2025
Q4 and FY2025 saw strong revenue and margin growth, led by demand in AI-driven consumer electronics, utilities, and energy sectors. FY2026 guidance calls for high single-digit revenue growth, stable to improving margins, and increased headcount, with AI adoption continuing to drive both opportunities and complexity.
Exponent sees FY26 revenue up in high single digits vs. FY25
Sees EBITDA 27.6%-28.1% of revenues before reimbursements.
Exponent sees Q1 revenue up in the high single digits
Sees Q1 EBITDA $27.5%-28.5% of revenues before reimbursements.
Exponent increases quarterly dividend to 31c per share for Q1
Exponent (EXPO) announced that its Board of Directors has raised its quarterly cash dividend from 30c to 31c per share of common stock. The quarterly cash dividend of 31c per
Exponent reports Q4 adjusted EPS 49c, consensus 47c
Reports Q4 revenue $147.43M, consensus $130.92M. “We delivered a strong finish to 2025 reflecting the strength, diversification, and resilience of our portfolio,” stated Dr. Catherine Corrigan, Presid...
Exponent Increases Quarterly Dividend Payment from $0.30 to $0.31 per Share for Q1 2026
MENLO PARK, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has raised its quarterly cash dividend from $0.30 to $0.31 per share of ...
Exponent Reports Fourth Quarter and Fiscal Year 2025 Financial Results
MENLO PARK, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the fourth quarter and fiscal year 2025 ended January 2, 2026.
Exponent initiated with an Overweight at JPMorgan
JPMorgan analyst Tomohiko Sano initiated coverage of Exponent (EXPO) with an Overweight rating and $100 price target representing 35% upside potential. Exponent is a leader in science and engineering ...
Exponent to Announce Fourth Quarter and Fiscal Year 2025 Results and Host Quarterly Conference Call on February 5, 2026
MENLO PARK, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report Fourth Quarter and fiscal year 2025 financial results for the period ended Janu...
Exponent price target raised to $81 from $76 at UBS
UBS raised the firm’s price target on Exponent (EXPO) to $81 from $76 and keeps a Neutral rating on the shares. Recent investor meetings left a positive impression, with management
Exponent upgraded to Outperform from Market Perform at William Blair
William Blair analyst Andrew Nicholas upgraded Exponent (EXPO) to Outperform from Market Perform. The firm believes strength in reactive demand, mid-single-digit headcount growth, and price realizatio...
Exponent price target lowered to $90 from $100 at Truist
Truist lowered the firm’s price target on Exponent (EXPO) to $90 from $100 and keeps a Buy rating on the shares. AI could be a beneficiary to engagements for Exponent